Amid the continuing angst over Brexit, the UK’s new Life Science Industrial Strategy recommends continued close alignment of the UK and EU regulatory systems and says steps should be taken to ensure the UK can continue to attract the most talented scientists and researchers from Europe and from the rest of the world.
The Life Sciences Industrial Strategy unveiled by Professor Sir John Bell on Aug. 30 contains a host of ideas on how to build up the £64bn sector into a “global hub” that will attract inward investment in a wide range of areas, and provide a “fertile environment” in which life sciences companies can flourish.
The strategy paints a picture of a UK science base supported by increased public funding where industry collaborates more closely...
The UK will require all antibiotic manufacturers looking to apply for funding under its subscription payment model to demonstrate they are meeting waste discharge standards in a bid to reduce antimicrobial resistance.
Pharmaceutical companies should only use AI in evidence generation and reporting where there is “demonstrable value from doing so,” according to England’s health technology assessment body, NICE.
While the drug regulator has approved Eisai/Biogen’s early Alzheimer’s disease treatment, the health technology assessment institute is worried that its benefits are too small to justify its costs – a concern that Eisai has pledged to address.
It is “absolutely fundamental” that manufacturers of cell and gene therapies interact with inspectors from regulatory agencies to understand their expectations around good manufacturing practice, a compliance consultant at CDMO eXmoor pharma says.
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
Companies dealing with commercial costings or contracts with the National Health Service for early phase clinical trials or trials of advanced therapy medicinal products should soon be able to conclude their negotiations more quickly.
As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.
